Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease of unknown etiology and uncertain pathogenic mechanisms. Recent studies indicate that the pathogenesis of the disease may involve the abnormal expression of certain developmental pathways. Here we evaluated the expression of Sonic Hedgehog (SHH), Patched-1, Smoothened, and transcription factors glioma-associated oncogene homolog (GLI)1 and GLI2 by RT-PCR, as well as their localization in IPF and normal lungs by immunohistochemistry. The effects of SHH on fibroblast proliferation, migration, collagen and fibronectin production, and apoptosis were analyzed by WST-1, Boyden chamber chemotaxis, RT-PCR, Sircol, and annexin V-propidium iodide binding assays, respectively. Our results showed that all the main components of the Sonic signaling pathway were overexpressed in IPF lungs. With the exception of Smoothened, they were also upregulated in IPF fibroblasts. SHH and GLI2 localized to epithelial cells, whereas Patched-1, Smoothened, and GLI1 were observed mainly in fibroblasts and inflammatory cells. No staining was detected in normal lungs. Recombinant SHH increased fibroblast proliferation (P Ͻ 0.05), collagen synthesis, (2.5 Ϯ 0.2 vs. 4.5 Ϯ 1.0 g of collagen/ml; P Ͻ 0.05), fibronectin expression (2-3-fold over control), and migration (190.3 Ϯ 12.4% over control, P Ͻ 0.05). No effect was observed on ␣-smooth muscle actin expression. SHH protected lung fibroblasts from TNF-␣/IFN-␥/Fas-induced apoptosis (14.5 Ϯ 3.2% vs. 37.3 Ϯ 7.2%, P Ͻ 0.0001). This protection was accompanied by modifications in several apoptosis-related proteins, including increased expression of X-linked inhibitor of apoptosis. These findings indicate that the SHH pathway is activated in IPF lungs and that SHH may contribute to IPF pathogenesis by increasing the proliferation, migration, extracellular matrix production, and survival of fibroblasts.
The Hedgehog signaling pathway is highly regulated, as it plays critical roles in embryonic development, tissue patterning, and organogenesis (14, 36) . There are three hedgehog homologs in mammals, Sonic hedgehog (SHH), Indian hedgehog (IHH), and Desert hedgehog (DHH) (1, 14) . Hedgehog signaling responses are mediated by PTCH1, a 12-pass integral membrane protein, and Smoothened (SMO), a seven-pass integral membrane protein (1) .
The three hedgehog homologs identified in humans have different spatial and temporal distribution patterns. SHH is the most broadly expressed, and it has been shown to be responsible for patterning the lung, where it is important for branching morphogenesis (25, 32) . By contrast, DHH and IHH have more restricted roles. Thus DHH expression is largely restricted to gonads (germ cells in the testis), whereas IHH is primarily involved in the development of long-bone growth and cartilage (1, 43, 47) .
During mouse lung development, SHH is highly expressed in the distal epithelium and diffuses from there to activate signaling in the nearby mesenchyme via PTCH1, SMO, and their transcriptional effectors glioma-associated oncogene homolog (GLI)1, GLI2, and GLI3 (1, 2, 15, 17, 42) . In mice lung development, Shh overexpression increases the ratio of interstitial mesenchyme to distal epithelial tubules, an effect that is most pronounced just before birth, when transgenic lungs contain excessive mesenchyme (2) .
Studies in human adult lungs have revealed overexpression of SHH in the alveolar epithelium of patients with IPF and other idiopathic interstitial pneumonias (6, 11, 44) . Likewise, upregulation of SHH has been also immunohistochemically detected in fibrotic remodeling after exposure to fluorescein isothiocyanate (10) . SHH is released by human type-II alveolar epithelial cells in vitro, which is stimulated by oxidative injury and inhibited by TGF-␤ (11) . However, studies of all the components of the SHH signaling pathway, as well as the effect of Sonic on adult human lung fibroblasts, have not been previously explored.
The present study was designed to examine the expression of all the components of this pathway, e.g., SHH, PTCH1, SMO, GLI1, and GLI2, in IPF lungs and to determine the effects of SHH on several cell processes in fibroblasts obtained from IPF and normal human lungs.
MATERIALS AND METHODS
This study was approved by the Science and Bioethical Committee at the National Institute of Respiratory Diseases.
Immunohistochemistry. We examined the localization of SHH, PTCH1, SMO, GLI1, and GLI2 in seven IPF and three normal lungs.
Immunohistochemical analysis was performed as described (31) . Briefly, lung sections were incubated for 18 h at 4°C with one of the following primary monoclonal antibodies: anti-SHH [Abcam/ ab73958 (1:100)], anti-PTCH1 [Abcam/ab27529 (1:50) and Novus Biologicals/NBP1-47945 (1:25), which was better to reveal positive staining in fibroblast foci], anti-SMO [Abcam/ab72130 (1:100)], anti-GLI1 [RayBiotech/805-820 (1:100) and Abcam/ab49314 (1:50), which allow a better observation of nuclear staining], anti-GLI2 [Abcam/ab26056 (1:700)]. Sections were incubated with a secondary biotinylated anti-immunoglobulin antibody followed by horseradish peroxidase-conjugated streptavidin (BioGenex, San Ramon, CA). 3-Amino-9-etilcarbazol in acetate buffer containing 0.05% H 2O2 was used as substrate. The primary antibody was replaced by nonimmune serum for negative control slides (31) .
Fibroblasts. Primary human IPF and normal lung fibroblasts were obtained as described (34) . The CCD25-Lu normal fibroblast cell line, which is derived from a seven-yr-old child was obtained from ATCC (Rockville, MA). We performed a dose-response pilot experiment using SHH from 50 ng/ml to 2 g/ml to evaluate several fibroblasts functions. We found that concentrations of 1.5 and 2.0 g/ml gave significant and reproducible results, and, accordingly, the dose of 2 g/ml was used for all fibroblasts experiments. This concentration has been widely used (7, 18, 21, 49) .
Laser capture microdissection. Fibroblasts from IPF and cryptogenic organizing pneumonia (COP) lungs were obtained by laser capture microdissection (LCM). Two pooled samples from three IPF lungs and two COP were used. Tissue samples were incubated first in the aqueous protection-solution HOPE (DCS; Innovative, Berlin, Germany) for 24 h (0 -4°C), then in a premixed ice-cold acetone solution (100 ml acetone and 100 l HOPE II solution) for 2 h, and then dehydrated in acetone (0 -4°C) for 2 h. Parafin-embedded tissues were microdissected on an Arcturus: PixCell IIe Laser capture microdissection system (28, 50) .
Real-time PCR. Total RNA was obtained from LCM samples using the PicoPure RNA Isolation kit (Arcturus). Total RNA from IPF tissues (n ϭ 7) and from human lung fibroblasts (3 primary cell cultures from control lungs, and 6 derived from IPF lungs) were extracted using the TRIzolTM reagent (Invitrogen Life Technologies, Grand Island, NY). For tissue control, we used six commercial human normal lung RNAs (Ambion AM7968, Agilent 540019, Origene HT1009, Zyagen HR-601, BD 64092-1, and USBiological T5595-7343). RNA was reverse transcribed into cDNA, and real-time PCR was performed using an Step One Real-Time PCR System (Applied Biosystems, Foster City, CA) with TaqMan probes labeled with FAM [Hs00970980_m1 for PTCH-1, Hs00164004_m1 for ␣1-type-I collagen, Hs00365052_m1 for fibronectin, Hs0109024_m1 for SMO, Hs00179843_m1 for SHH, Hs01110768_m1 for GLI 1, Hs01119974_ m1 for GLI 2, and 18S rRNA (4352930E) as endogenous control]. PCR was performed in a 25-l reaction volume containing 4 l of cDNA and PCR Master Mix 20ϫ (Applied Biosystems), and the PCR conditions were 2 min at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. A dynamic range was constructed for each PCR product on serial dilutions of copy number from 1 ϫ 10 10 to 1 ϫ 10 2 . All PCRs were performed in triplicate, and the results are expressed as the number of copies of the target gene normalized to 18S ribosomal RNA.
Western blot. Fibroblasts were stimulated with SHH (2 g/ml) in serum-free DMEM for 48 h and lysed with RIPA buffer (50 mM Tris·HCl, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1% Triton X-100, 1 mM NaF, 1 mM Na 3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml aprotinin). Protein concentration was quantified using the Bradford assay (Bio-Rad, Hercules CA). Aliquots containing 30 g of protein mixed with Laemmli sample buffer were used for electrophoresis on 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes blocked with 5% skim milk for 1 h and treated overnight at 4°C with monoclonal antibody anti-␣-smooth muscle actin (SMA) (1:200, A2547; Sigma Aldrich, St. Louis, MO), and rabbit anti-␤-tubulin (1:500; Santa Cruz Biotechnology, Santa Cruz, CA). The antibodies were detected using horseradish peroxidase-conjugated anti-mouse (31, 38) . Fibroblasts (2ϫ10 5 cells/well) resuspended in Ham's F-12 medium containing 5% BSA were added to the upper chamber. The lower chamber contained 0.5 ml of medium with 5% BSA alone or with 2 g/ml of recombinant human SHH (R&D Systems, Minneapolis, MN). To evaluate whether the effect of SHH on lung fibroblasts was mediated by PDGF-BB, specific neutralizing anti-PDGF-B antibody (2 g/ml) was used in parallel experiments (R&D Systems). Isotype IgG was used as a control. After incubation for 8 h at 37°C in a humidified incubator (5% CO 2-95% air), the nonmigrating cells remaining on top of the membrane were scraped and washed. The migrating cells were stained and the color eluted with 300 l of extraction buffer. Aliquots (150 l) were measured in an ELISA plate reader at 545 nm. All assays were performed in duplicate. Growth rate assay. Lung fibroblasts were seeded in 96-well culture plates at a cell density of 10ϫ10 3 and incubated in DMEM supplemented with 10% FBS at standard conditions. After 24 h, the medium was replaced by serum-free medium alone or with human recombinant SHH (2 g/ml), and the cells were maintained in culture for 48, 72, or 96 h. Cell growth was determined using the cell proliferation reagent WST-1 (Boehringer, Mannheim, Germany) as described (31) . All assays were performed in triplicate. In a parallel experiment, the growth rate of the CCD25-Lu fibroblast cell line was analyzed after treatment with 5 M cyclopamine a specific inhibitor of SHH signaling.
Apoptosis assay. Apoptosis was induced by incubating the fibroblasts with TNF-␣ (20 ng/ml) and IFN-␥ (50 ng/ml) for 48 h and then adding a FAS agonist (250 ng/ml) for additional 48 h (12). To evaluate the effect of SHH, fibroblasts were cultured after TNF-␣/ IFN-␥/FAS treatment with 2 g recombinant SHH for 48 h. Apoptosis was examined with the Annexin V-propidium iodide (PI) binding assay, followed by flow cytometry analysis (Annexin V-PE Apoptosis detection kit; BD Pharmingen, San Diego, CA) according to the manufacturer's instructions. Cells were acquired in a FACSAria flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Annexin-positive/ PI-negative (early apoptotic) cells and Annexin V-positive/PI-positive (apoptosed) cells were determined as percentages of the total cell population. Data were analyzed using FlowJo 7.8 software (Stanford University, Stanford, CA).
Human apoptosis antibody array. The expression profile of 35 apoptosis-related proteins was measured using a human apoptosis array kit (Proteome Profiler Array ARY009, R&D Systems) (35) . The membrane containing immobilized antibodies against apoptosis-related proteins was blocked for 1 h on a rocking platform at room temperature and then incubated with lysates (400 g) of untreated fibroblasts or fibroblasts treated with TNF-␣/IFN-␥/Fas, TNF-␣/IFN-␥/F␣s/SHH or SHH alone along with detection antibody cocktail overnight ␣t 2-8°C. The membrane was incubated with streptavidinhorseradish peroxidase conjugate followed by a chemiluminescent detection reagent. The membrane was scanned, and the resulting spots were visualized using chemiluminescence. Mean spot densities were quantified by densitometry. We expressed the data as fold change and arbitrarily considered as biologically important a change Ն20%. Collagen measurement. Collagen was quantified in cell-conditioned medium using the Sircol collagen assay (Biocolor, Belfast, UK) as described (29) .
Statistical analysis. Results are presented as means Ϯ SD. Differences were assessed by Tukey's test, Student's t-test, and MannWhitney U-test, and P Ͻ 0.05 was considered significant. Data were analyzed using GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego, CA).
RESULTS

IPF lungs overexpress the main components of the Sonic signaling pathway.
The gene expression of SHH, its receptor PTCH1, the coreceptor SMO, and the transcription factors GLI-1 and -2 was quantified by RT-PCR in IPF (n ϭ 7) and control lungs (n ϭ 6). As illustrated in Fig. 1 , all these genes were upregulated in IPF lungs compared with normal lungs. The highest expression was observed with Sonic.
Immunolocalization of SHH signaling pathway molecules. Immunohistochemical staining revealed that SHH, its receptor PTCH1, and the signaling molecules SMO, GLI1 and GLI2, were expressed in IPF lungs (n ϭ 7) but not in normal lungs (n ϭ 3; Figs. 2, 3, and 4), paralleling its low or absent gene expression. SHH was observed in bronchiolar and alveolar epithelial cells, in an apical distribution, and was occasionally noted in groups of basal/myoepithelial cells (Fig. 2, A and B) . PTCH1 was expressed in fibroblasts and some interstitial inflammatory cells (Fig. 2, E and F) , whereas strong immunostaining of the transmembrane coreceptor SMO was noted in interstitial inflammatory cells and mesenchymal cells forming fibroblast foci (Fig. 3, A and B) . Transcription factor GLI1 was found in epithelial cells, fibroblasts, and inflammatory cells (cytoplasmic and nuclear localization) (Fig. 3, E and F) , whereas GLI2 was observed in alveolar epithelial cells, predominantly in a nuclear distribution (Fig. 4, A and B) .
Sonic hedgehog activates the canonical pathway in normal and IPF fibroblasts. To confirm that the canonical hedgehog pathway is activated in lung fibroblasts downstream SMO, fibroblasts from normal and IPF lungs were stimulated with recombinant SHH and PTCH1, and GLI1 and GLI2 were evaluated by real-time PCR. As illustrated in fibroblasts obtained from six IPF lungs and three normal human lungs, as well as in the normal fibroblast cell line CCD25-Lu. As shown in Fig. 6 , with the exception of SMO, all SHH signaling pathway components were strongly upregulated in IPF fibroblasts. Interestingly, the fibroblast cell line CCD25-Lu consistently expressed higher amounts of the receptor PTCH1 compared with primary normal lung fibroblasts and was used for several functional experiments. We also examined the expresssion of PTCH1 by fibroblasts isolated from IPF fibroblastic foci and COP Masson bodies by laser capture microdissection and found threefold increased expression in IPF fibroblasts (not shown).
Sonic hedgehog increases fibroblast proliferation and collagen and fibronectin expression. Stimulation with SHH of either IPF fibroblasts or CCD25-Lu cell line (normal human lung fibroblasts that expresses the receptor PTCH1) induced increased proliferation. Using the WST-1 assay, differences between SHH-treated and control cells became statistically significant at 72 h for the CCD25-Lu cells and at 96 h for the IPF primary cells (Fig. 7) . To further corroborate the effect of SHH on fibroblast proliferation, we treated the cells with the specific inhibitor cyclopamine. Our results showed that cyclopamine abolished the effect of SHH. Interestingly, cyclopamine also inhibited the growth rate of control cells (Fig. 7A) . Prior evidence suggests that increased proliferation induced by SHH is mediated by a decrease in cAMP levels, and we consequently analyzed the levels of cAMP in SHH-treated and untreated lung fibroblasts by ELISA. SHH lowered cAMP levels, but the decrease was nonsignificant (5.6 Ϯ 1.1 vs. 6.9 Ϯ 0.9 pm/mg protein; P ϭ 0.2).
SHH also increased fibroblast collagen synthesis. As shown in Fig. 8A , ␣-1(I) collagen gene expression was significantly upregulated. Likewise, collagen protein in normal lung fibroblast (CCD25-Lu) culture supernatants increased from 2. . SHH increases collagen and fibronectin expression without effect on ␣-smooth muscle actin (SMA). Human lung fibroblasts were stimulated with 2 g/ml of SHH, and collagen synthesis was determined by quantitative RT-PCR and Sircol assay. A: at 24 h, SHH significantly increased the level of ␣1(I) collagen mRNA normalized to the level of 18S rRNA. B: at 48 h, SHH significantly enhanced the secretion of collagen protein in culture supernatants obtained from fibroblasts of 1 normal and 1 IPF lung; TGF-␤ was used as positive control (*P Ͻ 0.05; **P Ͻ 0.01). C: CCD25-Lu human normal lung fibroblasts and fibroblasts obtained from 2 IPF lungs were stimulated with 2 g/ml of SHH, and the expression of fibronectin at 6 h was analyzed by RT-PCR; **P Ͻ 0.01; ***P Ͻ 0.001. D: normal human lung fibroblasts were incubated in the presence of SHH for 72 h, and then total protein was extracted and Western blot analysis performed with specific antibodies for ␣-SMA. TGF-␤1 was used as a positive control.
0.2 to 4.5 Ϯ 1.0 g collagen/ml upon SHH stimulation, as assessed by Sircol assay (P Ͻ 0.05). Because SHH also induced fibroblast proliferation, we examined whether the observed increase of collagen was caused by an increase in the number of cells, and in a parallel experiment we adjusted the collagen production to the number of fibroblasts. The results confirmed that SHH drives fibroblast synthesis of collagen on both IPF and normal lung fibroblasts although its effect was lower than of TGF-␤ (Fig. 8B) . Cyclopamine partially inhibited this increase but has no effect on TGF-␤-induced collagen production. We also explored the effect of SHH on fibronectin expression. As shown in Fig. 8C , SHH stimulation induced a two-to threefold increase of fibronectin expression at 6 h in IPF fibroblasts, whereas a significant but smaller increase was detected in the normal cell line.
Because fibroblast differentiation to myofibroblasts plays an important role in the fibrogenic response, we explored whether SHH induces this process. As demonstrated in Fig. 8D , fibroblast treatment with SHH failed to increase their expression of ␣-SMA, a myofibroblasts marker, whereas TGF-␤1, a known inducer of this differentiation, strongly increased fibroblast ␣-SMA expression. Similar results were obtained with direct visualization of fibroblast ␣-SMA expression by immunofluorescence (not shown).
SHH protects fibroblasts from apoptosis. SHH reduced the basal (spontaneous) cell death in fibroblast cultures from 9.5 Ϯ 1.4% to 5.3 Ϯ 0.8%, P Ͻ 0.05. We then examined the ability of SHH to decrease cell death induced by the proapoptotic combination of TNF-␣/IFN-␥/FAS. TNF-␣ has been demonstrated to sensitize lung fibroblasts/myofibroblasts to apoptosis induced by Fas ligation, and IFN-␥ has been demonstrated to augment this response (12) . As illustrated in We then examined the effects of treating fibroblasts with SHH and/or TNF-␣/INF-␥/FAS on known apoptotic/antiapoptotic signaling molecules using a human apoptosis antibody array. Compared with control fibroblasts, SHH decreased fibroblast levels of HIF-1␣, SMAC/DIABLO, and TNFR1 (Fig. 10A) . TNF-␣/INF-␥/FAS increased several proapoptotic markers, most noticeably cleaved caspase 3, and decreased antiapoptotic proteins or cytoprotective factors, such as cellular inhibitor of apoptosis (cIAP)-1, Bax, heme oxygenase 1, and CDNK1A (Table 1) . SHH reduced these effects of TNF-␣/INF-␥/FAS treatment, decreasing the expression of cleaved caspase 3, HIF-1␣, and p53 [phosphorylated at Ser (46)], and increasing the expression cIAP-1, cIAP-2, and X-linked inhibitor of apoptosis (XIAP) (10B).
SHH induces fibroblast migration. SHH caused a significant increase of fibroblast migration (2.0-fold over control), as measured in modified Boyden chamber assays shown in Fig. 11 . This effect was slightly lower than to the that induced by PDGF-BB, a potent fibroblast chemoattractant. To determine whether SHH-induced migration was mediated by PDGF-BB, we added neutralizing antibody to this growth factor in our Boyden chamber assays. Neutralization of PDGF-BB significantly reduced SHH-induced fibroblast migration (P Ͻ 0.05), indicating that PDGF contributes to this migratory effect of SHH.
DISCUSSION
A growing body of evidence indicates that IPF is driven by aberrant epithelial-fibroblast communication, and recent reports support the hypothesis that this abnormal communication results at least in part from the reactivation of diverse developmental pathways (22, 41, 48) . Analyses of our own published datasets (31, 40, 51) with genes associated with lung development (41) . These upregulated development-associated genes included the Sonic Hedgehog receptor PTCH1. Likewise, pathway analyses of the predicted targets of differentially expressed microRNAs in IPF lungs demonstrated enrichment of targets belonging to the SHH pathway as well (30) .
Here, we first examined the gene expression of the main components of the SHH signaling pathway as well as their immunolocalization in the IPF lungs. Our results showed that this pathway is activated in IPF because all components examined, SHH, PTCH1, SMO, GLI1, and GLI2, were upregulated in the IPF lungs. SHH was observed mainly in the alveolar and bronchiolar epithelium, whereas its receptor PTCH1 was detected in mesenchymal cells in fibroblastic foci as well as in interstitial inflammatory cells. Previous studies have also found that SHH is expressed by lung epithelial cells, whereas the receptor has been additionally observed in macrophages and T-lymphocytes (6, 44) . The functional effect of the PTCH1 expression in mononuclear cells is uncertain, but recent work indicates that SHH is a potent chemoattractant for monocytes (9) . On the other hand, the role of SHH on T cell function is controversial. In peripheral T cells, the transcriptional changes induced by activation of this signaling pathway lead to reduced T cell activation (37) . However, hedgehog pathway activation on lymphocytes may contribute to the local expansion of invariant NKT cell populations during certain types of fibrosing liver damage (45) .
Interestingly, we also found the expression of the transcription factor GLI1 in both fibroblasts and inflammatory cells. By contrast, the SMO coreceptor was present mostly in fibroblastic foci, suggesting that the ligand of this pathway is produced by epithelial cells and signals through its receptor and coreceptor expressed by fibroblasts. However, a role of Sonic pathway in macrophage migration or lymphocyte functions cannot be ruled out. We also found robust overexpression of the SHH signaling pathway components in IPF fibroblasts compared with normal human lung fibroblasts. Moreover, fibroblasts obtained directly from fibroblastic foci through laser microdissection expressed significantly higher amounts of PTCH1 receptor compared with fibroblasts derived from Masson bodies of organizing pneumonia. SHH binding to PTCH1 abolishes SMO repression and causes signals to be delivered to the nucleus that activates the GLI transcription factors. Interestingly, whereas GLI1 was expressed by fibroblasts, GLI2 expression was localized to the epithelium, suggesting that SHH pathway signaling may also result in autocrine and/or paracrine activation of epithelial cells (Fig. 12) .
To determine whether SHH affects the behavior of fibroblasts, we explored the effect of this pathway on IPF and . SHH induces fibroblast migration. Normal human lung fibroblasts (CCD25-Lu) were seeded in the upper chamber of a Boyden chemotaxis chamber precoated with collagen. The lower chamber contained 0.5 ml of medium with 5% BSA alone or with 2 g/ml of recombinant human SHH. The fibroblast chemoattractant PDGF-BB (10 ng/ml) was used as positive control. Isotype IgG used as control had no effect. SHH increased cell migration significantly, and this effect was partially blocked by a specific anti-PDGF-B antibody (*P Ͻ 0.05).
normal human lung fibroblasts in several processes thought to be dysregulated in IPF, including migration, proliferation, apoptosis, collagen and fibronectin expression, and myofibroblast differentiation. Migration and proliferation are critical steps in wound healing, through which fibroblasts arrive and expand into injured sites. Excessive fibroblast migration and proliferation, in conjunction with subsequent exaggerated extracellular matrix synthesis, lead to fibrosis. We found evidence that the SHH may contribute to each of these processes.
Our results indicate that SHH is a strong chemoattractant for lung fibroblasts, and the finding that PDGF-BB neutralization attenuates SHH-induced fibroblast migration suggests that the chemotactic activity of SHH is partially attributable to this growth factor. Interestingly, a recent study suggests that, at least in mouse embryonic fibroblasts, SHH activation of small GTPases required for cell migration (Rac1 and RhoA) and SHH-induced fibroblast migration may occur by noncanonical pathway, independent of the engagement of GLI (33) . Likewise, our findings showed that SHH increases the proliferation of fibroblasts derived from normal or IPF lungs and enhanced their collagen and fibronectin expression. Increased collagen production has been also recently reported in skinderived fibroblasts from normal patients and patients with systemic sclerosis (16) . Because cross-communication between SHH and TGF-␤ pathways has been previously described (10, 24, 27) , we hypothesized that the effect of TGF-␤ on collagen production could be at least partially mediated by SHH. However, the use of the specific SHH inhibitor cyclopamine had no effect on the TGF-␤-induced collagen synthesis by lung fibroblasts.
Accumulating evidence indicates that the persistence of fibroblasts/myofibroblasts in the fibroblastic foci, likely related to resistance to apoptosis, also plays a critical role in the pathogenesis of IPF. However, the mechanisms responsible for this putative resistance of IPF fibroblasts to cell death are unclear (20, 26) . To evaluate the effects of the SHH pathway on this process in human lung fibroblasts, we induced cell death with TNF-␣ and IFN-␥ plus FAS (12) . We demonstrated that SHH has a potent antiapoptotic effect on fibroblasts, indicating that this signaling pathway may be at least partially involved in their resistance to apoptosis. To identify components of the apoptotic machinery of fibroblasts that may be responsive to SHH signaling, we employed a human apoptosis antibody array to analyze semiquantitatively changes in critical apoptosis and checkpoint pathway proteins. Our results showed that the alterations in the finely tuned balance of proapoptotic and antiapoptotic signals that are induced by TNF-␣/IFN-␥/FAS treatment are strongly counteracted by SHH. SHH increased fibroblast expression cIAP-1, cIAP-2, and XIAP, the most potent members of the IAP family, which suppress activation of the extrinsic cell death pathway induced by TNF-␣ signaling through TNF-R1 (8) . XIAP inhibits apoptosis by binding and inactivating the initiator caspase-9 and effector caspases (19) . A recent study indicates that regulation of XIAP expression by Hedgehog signaling is mediated by GLI2 because this transcription factor binds to the XIAP promoter and regulates its expression (23) . Interestingly, SHH decreased the fibroblast expression of the multifunctional HIF-1␣, which appears to have a dual role in cell fate. HIF-1␣ enhances cell survival in response to hypoxia but has been also associated with the induction of cell death in other settings (4, 5) . On the other hand, it is known that hypoxia induces a hedgehog response mediated by HIF-1␣, but the effect of SHH on HIF-1␣ expression is uncertain (3). Our results suggest that, under normoxic conditions, SHH decreases HIF-1␣ expression by fibroblasts, although whether this occurs by direct effect on the gene expression or indirect effect on the stability of the mRNA or protein is presently unknown. Finally, differentiation of fibroblasts to myofibroblasts was explored in human lung fibroblasts from several sources by two different techniques, without noting effects of SHH.
In summary, our findings demonstrated that the SHH signaling pathway is upregulated in IPF lungs, likely contributing to the pathogenesis of this disease. Specifically, SHH may contribute to the expansion (as a mitogen and chemoattractant) and survival of the fibroblast population, as well as to extra- Fig. 12 . Schematic model for the role of SHH in the pathogenesis of idiopathic pulmonary fibrosis. SHH produced by aberrantly activated alveolar epithelial cells functions as paracrine molecule on fibroblasts and perhaps also on neighboring epithelial cells. On fibroblasts, SHH binds to PTCH1 receptor, relieving Smoothened from the inhibitory effects of the receptor. Then, the transcriptional factor GLI is released from the kinase complex [i.e., protein kinase A (PKA), glycogen synthase kinase 3 (GSK3), casein kinase-1 (CK1)] to the cytoplasm, and migrates to the nucleus to bind specific target genes. SHH signaling on human lung fibroblasts induces an increase in fibroblast migration and proliferation and in the production of extracellular matrix (ECM) components such as collagen and fibronectin, as well as resistance to apoptosis. cellular matrix production. These results suggest that targeting the Sonic hedgehog pathway may be a promising therapeutic strategy for this devastating disease.
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